Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
AssigneeRiken
InventorsSoichi Kojima, Naoshi Dohmae, Wakako Kondo
Life of this patent
Estimating the term…
Abstract
It is an object of the present invention to provide antibodies capable of detecting an active TGF-β generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-β) generated as a result of generation of active form of human TGF-β1, human TGOF-β2 and human TGF-β3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-β1, and corresponding regions of human TGF-β2 and human TGF-β3.
Claims18
A method for detecting or measuring the activation reactions of human TGF-β1, human TGF-β2, and/or human TGF-β3 existing in samples or tissues comprising:
- staining or reacting a sample or tissue with an antibody against a latency-associated peptide (LAP) fragment of human TGF-β, which is able to specifically recognize a protease cleavage site within human TGF-β.
A method for diagnosing sclerotic diseases comprising:
- detecting or measuring the activation reactions of human TGF-β1, human TGF-β2, and/or human TGF-β3 existing in samples or tissues using an antibody against an LAP fragment of human TGF-β, which is able to specifically recognize a protease cleavage site within human TGF-β;
- and
- diagnosing sclerotic diseases based on the detection or measurement.
A method for detecting or measuring the activation reactions of human TGF-β1, human TGF-β2, and/or human TGF-β3 existing in samples or tissues comprising:
- staining or reacting a sample or tissue with using an antibody against an LAP fragment of human TGF-β1, human TGF-β2 and/or human TGF-β3, which is able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of SEQ ID NO:
- 1, and corresponding regions of human TGF-β2 and human TGF-β3.
Dependencies are inferred from the claim text.